Friday, 03 Apr 2020

You are here

EULAR Updates Gout Guidelines

A EULAR task force of 24 individuals (including 15 rheumatologists) have updated their previous 2006 guidelines for gout.  The current update is based on a systematic literature review and a Delphi consensus approach to recommendations.

Among the 11 key recommendations there were recommendations for :

  • Education
  • Non-pharmacological management
  • Frequent flares and contraindications to colchicine: NSAIDs and corticosteroids, or an interleukin-1 blocker could be considered.
  • Treatment of flare: colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), oral or intra-articular steroids or a combination are recommended.
  • Urate-lowering therapy (ULT) should be considered from the first presentation of the disease,
  • Prophylaxis against flares should be given during the first 6 months of ULT, with colchicine, 0.5–1 mg/day or with low dose NSAIDs.
  • Serum uric acid (SUA) levels should be maintained at <6 mg/dL (360 µmol/L) and <5 mg/dL (300 µmol/L) in those with severe (or tophaceous) gout.
  • Allopurinol is recommended as first-line ULT (dosage adjusted according to renal function).
  • With normal kidney function, the starting dose of allopurinol should be 100 mg/day, increasing by 100 mg increments every 2–4 weeks if required, to reach the uric acid target.
  • Febuxostat should be used if the SUA target cannot be achieved with allopurinol or if allopurinol is not tolerated.
  • Pegloticase is recommended for patients with refractory gout. 

The authors recognize that new data and new drugs will call for new guidelines and newer therapeutic strategies to improve the quality of gout care.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Interleukin-37 Targeting in Gout

The Annals of Rheumatic Disease reports that interleukin- 27 (IL-37) may play an important role in the pathogenesis of gout, paving the way for future therapy with recombinant IL-37 in gouty arthritis.

Activation of the inflammasome by monosodium urate crystals is thought to be paramount to the innate immune response that drives IL-1-mediated joint inflammation in gout.

Hyperuricemia Predisposes to Coronary Artery Disease in Men

There are numerous associations between hyperuricemia and cardiovascular disease (CVD). An analysis of the Swedish SCAPIS Pilot study shows that higher levels of serum urate (SU) are associated with an increase in coronary artery calcification score in men but not in women. SU is not associated with common carotid intima-media thickness and carotid plaque scores in either men or women.

Hypersensitivity Reactions and Gout Tx: Watch the Dose

Both allopurinol and febuxostat (Uloric) were associated with an increased risk of hypersensitivity reactions among new users of these urate-lowering therapies, a large U.S. study found.

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.